Press release
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:\n\nCiti’s 16th Annual BioPharma Virtual Conference – September 8-10, 2021\nSeptember 9, 2021 – Arrowhead management will host a day of virtual investor meetings\n\nHC Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021\nSeptember 13, 2021 – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\nBaird's 2021 Global Healthcare Conference – September 14-15, 2021\nSeptember 14, 2021, 4:55 p.m. ET – Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation\n\n2021 Cantor Virtual Global Healthcare Conference – September 27-30, 2021\nSeptember 29, 2021, 9:20 a.m. ET – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation\n\nA copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\nAbout Arrowhead Pharmaceuticals\n\nArrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.\n\nFor more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.\n\nSafe Harbor Statement under the Private Securities Litigation Reform Act:\n\nThis news release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limitin...